PathAI is a company.
PathAI has raised $75.0M across 3 funding rounds.
Key people at PathAI.
PathAI has raised $75.0M in total across 3 funding rounds.
Key people at PathAI.
PathAI has raised $75.0M in total across 3 funding rounds.
PathAI's investors include Abstract Ventures, Craft Ventures, General Catalyst, Gradient Ventures, Innovation Endeavors, Andy Rankin, Ashby Monk, Cherubic Ventures, DHVC (Digital Horizon Capital), Dynamo Ventures, Primitive Ventures, Y Combinator.
# PathAI: High-Level Overview
PathAI is an AI-focused technology company transforming pathology through artificial intelligence-powered diagnostic and research solutions.[1][2] Founded in 2016, PathAI develops comprehensive precision pathology solutions that improve the accuracy, efficiency, and reproducibility of tissue sample analysis for drug development, clinical diagnostics, and biomarker discovery.[2] The company serves biopharma companies, pathology laboratories, academic medical centers, and clinical research organizations—with over 15 of the top BioPharma companies leveraging its technology.[1]
PathAI addresses a critical problem in modern medicine: pathologists face high error rates and inconsistency when analyzing tissue samples manually, which slows drug development and delays accurate diagnoses.[2] The company solves this through AI models trained on data from over 450 pathologists and more than 15 million annotations, enabling tools that augment pathologist capabilities rather than replace them.[2] With 650 total employees across three offices and headquarters in Boston, Massachusetts, PathAI has achieved significant clinical validation and market traction.[3]
# Origin Story
PathAI was founded in 2016 by co-founders who identified a critical need for technology to reduce error rates and increase accuracy and reproducibility in pathology.[2] The company's trajectory reflects deliberate expansion into regulated healthcare markets. In 2019, PathAI achieved ISO 13485 and ISO 27001 certifications, establishing quality and security standards essential for medical device companies.[2]
A pivotal moment came in 2022 when PathAI built an in-house CAP/CLIA-certified GCLP histopathology laboratory to fully support end-to-end clinical trials for BioPharma partners—a significant capital investment signaling commitment to becoming an integrated service provider.[2] That same year, the company received FDA 510(k) clearance and CE Mark for AISight Dx, its digital pathology platform cleared for primary diagnosis in clinical settings.[2] By 2023, PathAI had launched over 20 cutting-edge AI products, including PathExplore, which analyzes tumor microenvironment features from tissue images.[2]
# Core Differentiators
# Role in the Broader Tech Landscape
PathAI operates at the intersection of three powerful trends: the digitization of healthcare, the maturation of deep learning for medical imaging, and the urgent need to accelerate drug development and improve diagnostic accuracy. The company is riding the broader shift toward precision medicine—using AI and biomarkers to tailor treatments to individual patients rather than applying one-size-fits-all approaches.[4]
The timing is critical. Pathology has historically been one of the last medical specialties to adopt digital workflows, creating a massive modernization opportunity. Simultaneously, regulatory bodies (FDA, EMA) are increasingly comfortable with AI-assisted diagnostics, as evidenced by PathAI's clearances.[2] The company's strategic collaborations with major institutions—including Northwestern Medicine and Moffitt Cancer Center—signal that academic medical centers and health systems are ready to integrate AI pathology tools into clinical practice.[5]
PathAI's influence extends beyond its direct customers. By demonstrating that AI can enhance rather than replace pathologists, the company is reshaping how the healthcare industry thinks about AI adoption in specialized medical domains. Its success validates the market for precision pathology solutions and attracts competition and investment to the space.
# Quick Take & Future Outlook
PathAI is positioned as a category leader in AI-powered pathology, with strong clinical validation, regulatory clearances, and a growing network of institutional partnerships. The company's next phase will likely focus on scaling clinical adoption of AISight Dx and expanding its AI product portfolio into new diagnostic areas beyond oncology.
Key trends to watch: (1) International expansion—CE Mark certification opens European markets; (2) Integration with electronic health records—connecting pathology AI insights to broader clinical workflows; (3) Spatial biology and biomarker discovery—emerging as a high-value use case for BioPharma partners; (4) Competitive pressure—larger diagnostics companies and AI firms are entering the space.
The fundamental thesis remains compelling: pathology is a bottleneck in drug development and patient care, and AI can measurably improve accuracy and speed. PathAI's combination of proprietary data, regulatory clearances, and institutional partnerships positions it well to capture significant value as precision medicine becomes standard practice.
PathAI has raised $75.0M across 3 funding rounds. Most recently, it raised $60.0M Series B in April 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2019 | $60.0M Series B | Abstract Ventures, Craft Ventures, General Catalyst, Gradient Ventures, Innovation Endeavors, Andy Rankin, Ashby Monk | |
| Nov 1, 2017 | $11.0M Series A | Cherubic Ventures, DHVC (Digital Horizon Capital), Dynamo Ventures, Primitive Ventures, Y Combinator, Andy Rankin, Pip Wilson | |
| Dec 1, 2016 | $4.0M Seed | 305 Ventures, AME Cloud Ventures, BITKRAFT Ventures, Borderless Capital, Brkfst Club, Cherubic Ventures, Kevin Ding, DHVC (Digital Horizon Capital), Dynamo Ventures, FJ Labs, Fusion Fund, Goodwater Capital, Great Oaks Venture Capital, Hardware Club, Jigsaw VC, KRM Interests LLC, Hans Tung, Pegasus Tech Ventures, Pillar VC, Primitive Ventures, Rebel Fund, Susquehanna Capital, Tiger Global Management, UpHonest Capital, Y Combinator, Andy Rankin, Harrison Uffindell, Mei Z., Nimit Maru, Pip Wilson |
